Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Ltd. Raises $12.8M in Private Financing

NEW YORK (GenomeWeb) – Genomics Ltd. has raised £10.3 million ($12.8 million) in a private round of financing, according to a statement released today by one of its investors, the IP Group.

The firm, which is a spinout from the University of Oxford in the UK, is developing a platform for genomic sequence data analysis. Its founders include Oxford Professors Peter Donnelly, who also is director of the Wellcome Trust Centre for Human Genetics, and Gil McVean. It is chaired by David Norwood, who was one of the founders of Oxford Nanopore Technologies.

Investors in the round included the IP Group and the University of Oxford, as well as new investors Invesco Perpetual, Lansdowne Partners, Woodford Investment Management and the Wylie Family Trust. The IP Group said that its nearly 17 percent stake in Genomics Ltd. is valued at £4.3 million, and including the holdings of an affiliated fund its effective beneficial interest in the firm is approximately 19 percent.

Last month, Genomics Ltd. was one of 10 firms selected to continue to the next assessment phase of the UK's 100,000 Genomes Project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.